li001

The phase 3 KEYNOTE-B96/ENGOT-ov65 trial (NCT05116189) showed that combining pembrolizumab (Keytruda) with weekly paclitaxel—with or without bevacizumab (Avastin)—improves survival in patients with platinum-resistant recurrent ovarian cancer (PROC). This is the first immune checkpoint inhibitor regimen to demonstrate a significant overall survival benefit in this setting. In 643 patients, the treatment improved median progression-free survival (PFS)

A new study points to the protein TRIM21 as a key driver of pancreatic adenocarcinoma (PAAD), one of the deadliest cancers with a 5-year survival rate below 9%. Using bioinformatics and lab experiments, researchers found that TRIM21 is highly overexpressed in pancreatic cancer tissues and strongly linked to poor patient outcomes. High levels of TRIM21

Researchers have developed a simple, cost-effective test to classify BRAF V600E–mutant colorectal cancer (CRC), advancing personalized therapy. The new immunohistochemistry (IHC)–based system, called iBM, uses two protein markers—CD8, indicating immune activity, and ARHGEF17, involved in cell-cycle regulation—to identify tumor subtypes without expensive genomic sequencing. The test categorizes tumors into two groups: iBM1, with high immune

Pirtobrutinib is a new therapy for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), especially in patients who have received multiple prior treatments. Unlike older BTK inhibitors, pirtobrutinib is a selective, noncovalent BTK inhibitor that binds reversibly and remains effective against the common C481S mutation causing resistance. In the Phase 1/2 BRUIN trial, it achieved an